JOP20240250A1 - مركبات واستخداماتها - Google Patents
مركبات واستخداماتهاInfo
- Publication number
- JOP20240250A1 JOP20240250A1 JOJO/P/2024/0250A JOP20240250A JOP20240250A1 JO P20240250 A1 JOP20240250 A1 JO P20240250A1 JO P20240250 A JOP20240250 A JO P20240250A JO P20240250 A1 JOP20240250 A1 JO P20240250A1
- Authority
- JO
- Jordan
- Prior art keywords
- vehicles
- cancer
- formula
- present disclosure
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340927P | 2022-05-11 | 2022-05-11 | |
| PCT/US2023/021793 WO2023220219A1 (en) | 2022-05-11 | 2023-05-11 | Compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20240250A1 true JOP20240250A1 (ar) | 2024-11-07 |
Family
ID=86732694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2024/0250A JOP20240250A1 (ar) | 2022-05-11 | 2024-11-07 | مركبات واستخداماتها |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US12139487B2 (https=) |
| EP (1) | EP4522280A1 (https=) |
| JP (2) | JP7531656B2 (https=) |
| KR (1) | KR20250024923A (https=) |
| CN (1) | CN119677738A (https=) |
| AR (1) | AR129299A1 (https=) |
| AU (1) | AU2023270055A1 (https=) |
| CA (1) | CA3252955A1 (https=) |
| CL (1) | CL2024003450A1 (https=) |
| CO (1) | CO2024015229A2 (https=) |
| DO (1) | DOP2024000231A (https=) |
| IL (1) | IL316531A (https=) |
| JO (1) | JOP20240250A1 (https=) |
| MX (1) | MX2024013838A (https=) |
| PE (1) | PE20250261A1 (https=) |
| TW (2) | TW202506693A (https=) |
| WO (1) | WO2023220219A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3198317A1 (en) * | 2020-11-10 | 2022-05-19 | Kevin J. Wilson | Compounds and uses thereof |
| CN121443603A (zh) * | 2023-07-05 | 2026-01-30 | 詹森药业有限公司 | 能够用于治疗smarca4缺失型癌症的作为smarca2抑制剂的1,6-萘啶化合物 |
| WO2025099307A1 (en) * | 2023-11-10 | 2025-05-15 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of diseases |
| US20250304542A1 (en) * | 2024-03-11 | 2025-10-02 | Enanta Pharmaceuticals, Inc. | Fused Heterobicyclic Antiviral Agents |
| WO2025209520A1 (zh) * | 2024-04-03 | 2025-10-09 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其用途 |
| WO2025237242A1 (zh) * | 2024-05-14 | 2025-11-20 | 上海和誉生物医药科技有限公司 | 一种smarca2抑制剂及其应用 |
| CN118930537B (zh) * | 2024-07-23 | 2025-05-13 | 上海信诺维生物医药有限公司 | 一种抑制brm的化合物 |
| CN118930561B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种稠环化合物 |
| CN118908980B (zh) * | 2024-07-23 | 2025-04-08 | 上海信诺维生物医药有限公司 | 一种多环化合物 |
| WO2026046365A1 (zh) * | 2024-08-30 | 2026-03-05 | 上海齐鲁制药研究中心有限公司 | Smarca2抑制剂及其制备方法和用途 |
| WO2026057002A1 (zh) * | 2024-09-12 | 2026-03-19 | 江苏恒瑞医药股份有限公司 | 一种烯炔类化合物及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200801012A (en) | 2006-04-26 | 2008-01-01 | Piramed Ltd | Phosphoinositide 3-kinase inhibitor compounds and methods of use |
| US9050345B2 (en) | 2013-03-11 | 2015-06-09 | Bristol-Myers Squibb Company | Pyrrolotriazines as potassium ion channel inhibitors |
| WO2015095788A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | 2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| JP6759514B2 (ja) | 2014-08-01 | 2020-09-23 | ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ | ブロモドメインに対して活性な化合物 |
| WO2021155264A1 (en) | 2020-01-29 | 2021-08-05 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| AU2021213811A1 (en) * | 2020-01-29 | 2022-07-28 | Foghorn Therapeutics Inc. | Compounds and uses thereof |
| EP4096667A4 (en) * | 2020-01-29 | 2024-03-06 | Foghorn Therapeutics Inc. | COMPOUNDS AND USES THEREOF |
| CN115484948A (zh) * | 2020-01-29 | 2022-12-16 | 福宏治疗公司 | 化合物及其用途 |
| US12383555B2 (en) | 2020-05-20 | 2025-08-12 | Foghorn Therapeutics Inc. | Methods of treating cancers |
| CA3198317A1 (en) * | 2020-11-10 | 2022-05-19 | Kevin J. Wilson | Compounds and uses thereof |
-
2023
- 2023-05-11 AR ARP230101168A patent/AR129299A1/es unknown
- 2023-05-11 JP JP2023078608A patent/JP7531656B2/ja active Active
- 2023-05-11 US US18/315,526 patent/US12139487B2/en active Active
- 2023-05-11 CA CA3252955A patent/CA3252955A1/en active Pending
- 2023-05-11 CN CN202380053231.6A patent/CN119677738A/zh active Pending
- 2023-05-11 PE PE2024002469A patent/PE20250261A1/es unknown
- 2023-05-11 AU AU2023270055A patent/AU2023270055A1/en active Pending
- 2023-05-11 TW TW113141340A patent/TW202506693A/zh unknown
- 2023-05-11 IL IL316531A patent/IL316531A/en unknown
- 2023-05-11 TW TW112117604A patent/TWI864749B/zh active
- 2023-05-11 WO PCT/US2023/021793 patent/WO2023220219A1/en not_active Ceased
- 2023-05-11 EP EP23729898.9A patent/EP4522280A1/en active Pending
- 2023-05-11 KR KR1020247041093A patent/KR20250024923A/ko active Pending
-
2024
- 2024-07-30 JP JP2024122975A patent/JP2024156779A/ja active Pending
- 2024-10-25 US US18/926,578 patent/US20250066354A1/en active Pending
- 2024-11-07 JO JOJO/P/2024/0250A patent/JOP20240250A1/ar unknown
- 2024-11-07 CO CONC2024/0015229A patent/CO2024015229A2/es unknown
- 2024-11-08 MX MX2024013838A patent/MX2024013838A/es unknown
- 2024-11-11 DO DO2024000231A patent/DOP2024000231A/es unknown
- 2024-11-11 CL CL2024003450A patent/CL2024003450A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR129299A1 (es) | 2024-08-07 |
| TWI864749B (zh) | 2024-12-01 |
| EP4522280A1 (en) | 2025-03-19 |
| JP7531656B2 (ja) | 2024-08-09 |
| MX2024013838A (es) | 2025-03-07 |
| CL2024003450A1 (es) | 2025-03-14 |
| TW202411228A (zh) | 2024-03-16 |
| CN119677738A (zh) | 2025-03-21 |
| CA3252955A1 (en) | 2023-11-16 |
| JP2023168298A (ja) | 2023-11-24 |
| CO2024015229A2 (es) | 2025-03-06 |
| US20230365560A1 (en) | 2023-11-16 |
| JP2024156779A (ja) | 2024-11-06 |
| IL316531A (en) | 2024-12-01 |
| PE20250261A1 (es) | 2025-01-29 |
| KR20250024923A (ko) | 2025-02-20 |
| US20250066354A1 (en) | 2025-02-27 |
| US12139487B2 (en) | 2024-11-12 |
| AU2023270055A1 (en) | 2024-11-28 |
| TW202506693A (zh) | 2025-02-16 |
| DOP2024000231A (es) | 2024-12-15 |
| WO2023220219A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20240250A1 (ar) | مركبات واستخداماتها | |
| ZA202403923B (en) | Heterocyclic compounds as immunomodulators | |
| JOP20230318A1 (ar) | مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1 | |
| JOP20190151B1 (ar) | مركبات أمينو - ترايازولو بيريدين واستخدامها في علاج سرطان | |
| JOP20200315A1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
| MY209609A (en) | Immunomodulators, compositions and methods thereof | |
| CR20230566A (es) | Derivados de triazina y su uso en el tratamiento del cáncer | |
| JOP20230277A1 (ar) | مثبطات الكرومينون الألستيرية للفوسفونوسيتيد 3-كيناز (pi3k) لعلاج الأمراض | |
| WO2019139899A8 (en) | Benzamide compounds | |
| MX2022009043A (es) | Compuestos de sulfonimidamida como moduladores de nlrp3. | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| MX2024013842A (es) | Benzoyparazina pirazinas y sus usos | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| EP4316504A3 (en) | Compounds | |
| ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
| EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| MX2020008746A (es) | Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado. | |
| JOP20190179A1 (ar) | نوكليوتيدات ثنائية حلقية كناهضات لـ sting | |
| JOP20230275A1 (ar) | معدلات trex1 | |
| MX2025001062A (es) | Derivados de heteroaril sulfonamida biciclicos sustituidos para el tratamiento del cancer | |
| JOP20240130A1 (ar) | مثبطات تفاعل منين-mll | |
| MX2024013840A (es) | Derivados de pirazina y usos de los mismos |